The Mortality Risk of Androgen Inhibitors for Prostate Cancer and Heart Disease: An Interview with Grace Lu-Yao, PhD, MPH

Abiraterone acetate and enzalutamide are oral androgen signaling inhibitor therapies used in the treatment of patients with advanced prostate cancer. However, because elderly patients with prostate cancer who also have cardiovascular disease are often excluded from clinical trials, little has been known about the effect of these therapies on the clinical outcomes of these patients. In this interview with i3 Health, Grace Lu-Yao, PhD, MPH, discusses the increased mortality and hospitalization ris...
Continue reading

Androgen Inhibitors for Prostate Cancer and Heart Disease

Abiraterone acetate and enzalutamide, two oral androgen signaling inhibitor therapies, have been found to increase mortality in elderly patients with advanced prostate cancer and pre-existing cardiovascular disease (CVD). Many of the clinical trials which led to the approval of abiraterone acetate and enzalutamide for the treatment of advanced prostate cancer excluded elderly patients, defined as those age 65 and older, with cardiovascular comorbidities, such as congestive heart failure, atrial ...
Continue reading

Optimizing Prostate Cancer Detection: Interview With Johannes Czernin, MD

There is a discrepancy in guideline recommendations regarding prostate cancer detection; National Comprehensive Cancer Network (NCCN) guidelines recommend using 18 F-fluciclovine PET-CT for prostate cancer biochemical recurrence localization after radical prostatectomy as opposed to European Association of Urology (EAU) guidelines, which recommend prostate-specific membrane antigen (PSMA) PET-CT. Jeremie Calais, MD, Johannes Czernin, MD, and colleagues compared using 18 F-fluciclovine PET-CT ver...
Continue reading

Darolutamide Approved in Nonmetastatic CRPC

The FDA has now approved darolutamide (Nubeqa®, Bayer), an androgen receptor antagonist, for the treatment of nonmetastatic castration-resistant prostate cancer (CRPC). The approval was based on the ARAMIS phase 3 trial (NCT02200614), which enrolled 1,509 patients with nonmetastatic CRPC and a prostate-specific antigen doubling time of 10 months or less. Patients were randomized in a 2:1 ratio to receive darolutamide or placebo along with continued androgen deprivation therapy for a primary end ...
Continue reading

Androgen Deprivation and Dementia Risk in Prostate Cancer: Tanya Dorff, MD

Androgen deprivation therapy (ADT) is an effective treatment for high-risk prostate cancer in all stages of the disease. However, Ravishankar Jayadevappa, PhD, and colleagues found in a recent population-based study that this commonly used treatment increases diagnoses of dementia and Alzheimer's disease . In this interview with i3 Health, Tanya Dorff, MD, Associate Clinical Professor and Head of the Genitourinary Cancers Program at City of Hope, discusses the study's findings and their potentia...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.